Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14% on an operational basis due to ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

dosages of the Pfizer-BioNTech vaccine. Other vaccines (such as Moderna) were excluded from analyses. The final older (12-17 ...

Health Canada has approved Moderna's mRNA vaccine to protect against ... and Abrysvo, made by Pfizer. Earlier this year, the National Advisory Committee on Immunization recommended RSV ...

Both the Moderna and Pfizer/BioNTech actions are being heard in a Delaware district court. The lawsuits contribute to an ongoing bun fight between various parties involved in mRNA vaccines ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Antibiotics marked the transition to the modern Pfizer. Their follow-up to penicillin, Terramycin, first marketed in 1950, was both their first proprietary drug, and the first for which the ...